NCT00099437 2026-03-18
CONFIRM
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT05654623 2026-03-18
VERITAC-2
Pfizer
Phase 3 Active not recruiting
NCT06016738 2026-03-13
OPERA-01
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06065748 2026-03-09
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT06982521 2026-03-03
ReDiscover-2
Relay Therapeutics, Inc.
Phase 3 Recruiting
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT05038735 2026-02-20
EPIK-B5
Novartis
Phase 3 Active not recruiting